Whilst elevation of MCL-1 may bestow a competitive advantage on breast cancer cells during tumor development and prevent tumor cell elimination in response to therapy, the reliance on MCL-1 for survival also represents a vulnerability that could be utilized to improve treatment outcome in breast cancer. The gene discussed is MCL1; the disease is breast carcinoma.